Imperial College London

ProfessorEricAboagye

Faculty of MedicineDepartment of Surgery & Cancer

Professor
 
 
 
//

Contact

 

+44 (0)20 3313 3759eric.aboagye

 
 
//

Assistant

 

Mrs Maureen Francis +44 (0)20 7594 2793

 
//

Location

 

GN1Commonwealth BuildingHammersmith Campus

//

Summary

 

Publications

Publication Type
Year
to

351 results found

Buluwela L, Pike J, Mazhar D, Kamalati T, Hart SM, Al-Jehani R, Yahaya H, Patel N, Sarwarl N, Heathcote DA, Schwickerath O, Phoenix F, Hill R, Aboagye E, Shousha S, Waxman J, Lemoine NR, Zelent A, Coombes RC, Ali Set al., 2005, Inhibiting estrogen responses in breast cancer cells using a fusion protein encoding estrogen receptor-alpha and the transcriptional repressor PLZF (vol 12, pg 452, 2005), GENE THERAPY, Vol: 12, Pages: 862-862, ISSN: 0969-7128

Journal article

Buluwela L, Pike J, Mazhar D, Kamalati T, Hart SM, Al-Jehani R, Yahaya H, Patel N, Sarwarl N, Heathcote DA, Schwickerath O, Phoenix F, Hill R, Aboagye E, Shousha S, Waxman J, Lemoine NR, Zelent A, Coombes RC, Ali Set al., 2005, Inhibiting estrogen responses in breast cancer cells using a fusion protein encoding estrogen receptor-alpha and the transcriptional repressor PLZF, GENE THERAPY, Vol: 12, Pages: 452-460, ISSN: 0969-7128

Journal article

Barthel H, Perumal M, Latigo J, He QM, Brady F, Luthra SK, Price PM, Aboagye EOet al., 2005, The uptake of 3 '-deoxy-3 '-[F-18]fluorothymidine into L5178Y tumours in vivo is dependent on thymidine kinase 1 protein levels, EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, Vol: 32, Pages: 257-263, ISSN: 1619-7070

Journal article

Buluwela L, Pike J, Mazhar D, Kamalati T, Hart SM, Al-Jehani R, Yahaya H, Patel N, Sarwar N, Heathcote DA, Schwickerath O, Phoenix F, Hill R, Aboagye E, Shousha S, Waxman J, Lemoine NR, Zelent A, Coombes RC, Ali Set al., 2005, Inhibiting estrogen responses in breast cancer cells using a fusion protein encoding estrogen receptor-alpha and the transcriptional repressor PLZF (vol 12, pg 452, 2005), GENE THERAPY, Vol: 12, Pages: 552-552, ISSN: 0969-7128

Journal article

Aboagye EO, 2005, Positron emission tomography imaging of small animals in anticancer drug development, MOLECULAR IMAGING AND BIOLOGY, Vol: 7, Pages: 53-58, ISSN: 1536-1632

Journal article

Yatham LN, Liddle PF, Lam RW, Adam MJ, Solomons K, Chinnapalli M, Ruth TJet al., 2005, A positron emission tomography study of the effects of treatment with valproate on brain 5-HT2A receptors in acute mania., Bipolar Disord, Vol: 7 Suppl 5, Pages: 53-57, ISSN: 1398-5647

OBJECTIVE: To examine the effects of treatment with valproate on brain 5-HT2A receptors in acute manic patients using positron emission tomography (PET) and [18F]-setoperone. METHODS: Patients with DSM-IV bipolar I disorder-manic episode were recruited. Patients were drug free or drug naïve at the time of baseline PET scan. All patients were treated with valproate and one patient received lithium in addition to valproate for 3-5 weeks following which they had a post-treatment PET scan. The effect of treatment on brain 5-HT2A receptor binding was determined using statistical parametric mapping (SPM) and region of interest (ROI) analyses. Of the 12 manic patients recruited, seven patients had both baseline and post-treatment PET scans. RESULTS: All seven patients improved with treatment and were in remission at the time of the second PET scan. Both SPM and ROI analyses showed that treatment with mood stabilizers had no significant effect on brain 5-HT2A receptor binding in manic patients. CONCLUSION: This study suggests that changes in brain 5-HT2A receptors are not involved in the antimanic effects of mood stabilizers however, we cannot exclude the possibility of 5-HT2A receptor involvement in down-stream signaling pathways.

Journal article

Aboagye EO, PET imaging of small animals in anticancer drug development, Molecular Imaging in Biology, Vol: 7, Pages: 53-58

Journal article

Sanderson L, Taylor GW, Aboagye EO, Alao JP, Latigo JR, Coombes RC, Vigushin DMet al., 2004, Plasma pharmacokinetics and metabolism of the histone deacetylase inhibitor trichostatin A after intraperitoneal administration to mice, DRUG METABOLISM AND DISPOSITION, Vol: 32, Pages: 1132-1138, ISSN: 0090-9556

Journal article

Kenny LM, Al-Nahhas A, Vigushin D, Coombes RC, Aboagye EOet al., 2004, [F-18]Fluorothymidine retention in breast cancer measured by PET - Initial results from a pilot study, Annual Congress of the European-Association-of-Nuclear-Medicine, Publisher: SPRINGER, Pages: S328-S328, ISSN: 1619-7070

Conference paper

Groot-Wassink T, Aboagye EO, Wang YH, Lemoine NR, Keith WN, Vassaux Get al., 2004, Noninvasive imaging of the transcriptional activities of human telomerase promoter fragments in mice, CANCER RESEARCH, Vol: 64, Pages: 4906-4911, ISSN: 0008-5472

Journal article

Kenny L, Al-Nahhas A, Shousha S, Osman S, Vigushin DM, Coombes RC, Aboagye EOet al., 2004, Determination of [F-18]fluorothymidine kinetics in tumour and normal tissues of patients with breast cancer using positron emission tomography., British Cancer Research Meeting 2004, Publisher: NATURE PUBLISHING GROUP, Pages: S44-S44, ISSN: 0007-0920

Conference paper

Barthel H, Wilson H, Collingridge DR, Brown G, Osman S, Luthra SK, Brady F, Workman P, Price PM, Aboagye EOet al., 2004, In vivo evaluation of [F-18]fluoroetanidazole as a new marker for imaging tumour hypoxia with positron emission tomography, BRITISH JOURNAL OF CANCER, Vol: 90, Pages: 2232-2242, ISSN: 0007-0920

Journal article

Malik N, Luthra SK, Burke P, Price PM, Aboagye EO, Latigo J, Zhao YJ, Brady Fet al., 2004, Radiosynthesis of 4-[(2-chloroethyl)(2-[C-11]ethyl)amino]-phenoxycarbonyl-L-glutamic acid a half mustard prodrug as a potential probe for imaging antibody- and gene-directed enzyme prodrug therapy with positron emission tomography, APPLIED RADIATION AND ISOTOPES, Vol: 60, Pages: 825-834, ISSN: 0969-8043

Journal article

Kenny LM, Aboagye EO, Price PM, 2004, Positron emission tomography imaging of cell proliferation in oncology, CLINICAL ONCOLOGY, Vol: 16, Pages: 176-185, ISSN: 0936-6555

Journal article

Groot-Wassink T, Aboagye EO, Wang YH, Lemoine NR, Reader AJ, Vassaux Get al., 2004, Quantitative imaging of Na/I symporter transgene expression using positron emission tomography in the living animal, MOLECULAR THERAPY, Vol: 9, Pages: 436-442, ISSN: 1525-0016

Journal article

Barthel H, Price P, Aboagye EO, 2004, Advances in research - Small-animal imaging of tumour proliferation with PET, LANCET ONCOLOGY, Vol: 5, Pages: 100-100, ISSN: 1470-2045

Journal article

Cobben DCP, Elsinga PH, van Waarde A, Jager PLet al., 2003, Correspondence re: H. Barthel et al., 3 '-deoxy-3 '-[F-18]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res., 63: 3791-3798,2003., CANCER RESEARCH, Vol: 63, Pages: 8558-8559, ISSN: 0008-5472

Journal article

Collingridge DR, Glaser M, Osman S, Barthel H, Hutchinson OC, Luthra SK, Brady F, Bouchier-Hayes L, Martin SJ, Workman P, Price P, Aboagye EOet al., 2003, In vitro selectivity, in vivo biodistribution and tumour uptake of annexin V radiolabelled with a positron emitting radioisotope, British Journal of Cancer, Vol: 89, Pages: 1327-1333, ISSN: 0007-0920

The availability of a noninvasive method to detect and quantify apoptosis in tumours will enable tumour response to several cancer therapies to be assessed. We have synthesised two radiotracers, annexin V and the N-succinimidyl-3-iodobenzoic acid (SIB) derivative of annexin V, labelled with radio-iodine (124I and 125I) and provided proof of the concept by assessing specific binding and biodistribution of these probes to apoptotic cells and tumours. We have also assessed the tumour uptake of [124I]annexin V in a mouse model of apoptosis. RIF-1 cells induced to undergo apoptosis in vitro showed a drug concentration-dependent increased binding of [125I]annexin V and [125I]SIB–annexin V. In the same model system, there was an increase in terminal deoxynucleotidyl transferase-mediated nick end labelling (TUNEL)-positive cells and a decrease in clonogenic survival. Radiotracer binding was completely inhibited by preincubation with unlabelled annexin V. In RIF-1 tumour-bearing mice, rapid distribution of [125I]SIB–annexin V-derived radioactivity to kidneys was observed and the radiotracer accumulated in urine. The binding of [125I]SIB–annexin V to RIF-1 tumours increased by 2.3-fold at 48 h after a single intraperitoneal injection of 5-fluorouracil (165 mg kg−1 body weight), compared to a 4.4-fold increase in TUNEL-positive cells measured by immunostaining. Positron emission tomography images with both radiotracers demonstrated intense localisation in the kidneys and bladder. Unlike [124I]SIB–annexin V, [124I]annexin V also showed localisation in the thyroid region presumably due to deiodination of the radiolabel. [124I]SIB–annexin V is an attractive candidate for in vivo imaging of apoptosis by PET.

Journal article

Barthel H, Cleij MC, Collingridge DR, Hutchinson OC, Osman S, He QM, Luthra SK, Brady F, Price PM, Aboagye EOet al., 2003, 3 '-deoxy-3 '-[F-18]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography, CANCER RESEARCH, Vol: 63, Pages: 3791-3798, ISSN: 0008-5472

Journal article

Saleem A, Brown GD, Brady F, Aboagye EO, Osman S, Luthra SK, Ranicar ASO, Brock CS, Stevens MFG, Newlands E, Jones T, Price Pet al., 2003, Metabolic activation of temozolomide measured in vivo using positron emission tomography, CANCER RESEARCH, Vol: 63, Pages: 2409-2415, ISSN: 0008-5472

Journal article

Wells P, Aboagye E, Gunn RN, Osman S, Boddy AV, Taylor GA, Rafi I, Hughes AN, Calvert AH, Price PM, Newell DRet al., 2003, 2-[<sup>11</sup>C]thymidine positron emission tomography as an indicator of thymidylate synthase inhibition in patients treated with AG337, Journal of the National Cancer Institute, Vol: 95, Pages: 675-682, ISSN: 0027-8874

Background: Some anticancer drugs inhibit thymidylate synthase (TS), a key enzyme for thymidine nucleotide biosynthesis. Cells can compensate for depleted thymidine levels by taking up extracellular thymidine via a salvage pathway. We investigated the use of 2-[11C]thymidine positron emission tomography (PET) to measure thymidine salvage kinetics in vivo in humans. Methods: Five patients with advanced gastrointestinal cancer were PET scanned both before and 1 hour after oral administration of the TS inhibitor AG337 (THYMITAQ [nolatrexed]); seven control patients were scanned twice but not treated with AG337. Thymidine salvage kinetics were measured in vivo using 2-[11C]thymidine PET and spectral analysis to obtain the standardized uptake values (SUV), the area under the time-activity curve (AUC), and the fractional retention of thymidine (FRT). Changes in PET parameters between scans in the AG337-treated and control groups were compared using the Mann-Whitney U test. The relationship between AG337 exposure and AG337-induced changes in tumor FRT and in plasma deoxyuridine levels (a conventional pharmacodynamic systemic measure of TS inhibition) was examined using Spearman's regression analysis. Statistical tests were two-sided. Results: The between-scan change in FRT in patients treated with AG337 (38% increase, 95% confidence interval [CI] = 8% to 68%) was higher than that in control patients (3% increase, 95% CI = -11% to 17%) (P =.028). The level of AG337-induced increase in both 2-[11C]thymidine FRT and plasma deoxyuridine levels was statistically significantly correlated with AG337 exposure (r = 1.00, P =.01 for both). Conclusions: AG337 administration was associated with increased tumor tracer retention that was consistent with tumor cell uptake of exogenous 2-[11C]thymidine as a result of TS inhibition. 2-[11C]Thymidine PET can be used to measure thymidine salvage kinetics directly in the tissue of interest.

Journal article

Aboagye EO, Price PM, 2003, Use of positron emission tomography in anticancer drug development, INVESTIGATIONAL NEW DRUGS, Vol: 21, Pages: 169-181, ISSN: 0167-6997

Journal article

Propper DJ, de Bono J, Saleem A, Ellard S, Flanagan E, Paul J, Ganesan TS, Talbot DC, Aboagye EO, Price P, Harris AL, Twelves Cet al., 2003, Use of positron emission tomography in pharmacokinetic studies to investigate therapeutic advantage in a phase I study of 120-hour intravenous infusion XR5000, JOURNAL OF CLINICAL ONCOLOGY, Vol: 21, Pages: 203-210, ISSN: 0732-183X

Journal article

Hutchinson OC, Collingridge DR, Barthel H, Price PM, Aboagye EOet al., 2003, Pharmacodynamics of radiolabelled anticancer drugs for positron emission tomography, CURRENT PHARMACEUTICAL DESIGN, Vol: 9, Pages: 931-944, ISSN: 1381-6128

Journal article

Glaser M, Collingridge DR, Aboagye EO, Bouchier-Hayes L, Hutchinson OC, Martin SJ, Price P, Brady F, Luthra SKet al., 2003, Iodine-124 labelled Annexin-V as a potential radiotracer to study apoptosis using positron emission tomography, APPLIED RADIATION AND ISOTOPES, Vol: 58, Pages: 55-62, ISSN: 0969-8043

Journal article

Walledge RJ, Reader AJ, Aboagye EO, Spinks TJ, Honer M, Missimer J, Jeavons APet al., 2003, 4D PET with the quad-HIDAC: Development of dynamic list-mode EM image reconstruction, IEEE Nuclear Science Symposium/Medical Imaging Conference (NSS/MIC), Publisher: IEEE, Pages: 1716-1720, ISSN: 1095-7863

Conference paper

Hutchinson OC, Collingridge DR, Barthel H, Price PM, Aboagye EOet al., 2003, Pharmacokinetics of radiolabelled anticancer drugs for positron emission tomography, CURRENT PHARMACEUTICAL DESIGN, Vol: 9, Pages: 917-929, ISSN: 1381-6128

Journal article

Wells P, Aboagye E, Gunn RN, Osman S, Boddy AV, Taylor GA, Rafi I, Hughes AN, Calvert AH, Price PM, Newell DRet al., 2003, 2-[11C]thymidine positron emission tomography as an indicator of thymidylate synthase inhibition in patients treated with AG337, J Natl Cancer Inst, Vol: 95, Pages: 675-682, ISSN: 1460-2105

BACKGROUND: Some anticancer drugs inhibit thymidylate synthase (TS), a key enzyme for thymidine nucleotide biosynthesis. Cells can compensate for depleted thymidine levels by taking up extracellular thymidine via a salvage pathway. We investigated the use of 2-[11C]thymidine positron emission tomography (PET) to measure thymidine salvage kinetics in vivo in humans. METHODS: Five patients with advanced gastrointestinal cancer were PET scanned both before and 1 hour after oral administration of the TS inhibitor AG337 (THYMITAQ [nolatrexed]); seven control patients were scanned twice but not treated with AG337. Thymidine salvage kinetics were measured in vivo using 2-[11C]thymidine PET and spectral analysis to obtain the standardized uptake values (SUV), the area under the time-activity curve (AUC), and the fractional retention of thymidine (FRT). Changes in PET parameters between scans in the AG337-treated and control groups were compared using the Mann-Whitney U test. The relationship between AG337 exposure and AG337-induced changes in tumor FRT and in plasma deoxyuridine levels (a conventional pharmacodynamic systemic measure of TS inhibition) was examined using Spearman's regression analysis. Statistical tests were two-sided. RESULTS: The between-scan change in FRT in patients treated with AG337 (38% increase, 95% confidence interval [CI] = 8% to 68%) was higher than that in control patients (3% increase, 95% CI = -11% to 17%) (P =.028). The level of AG337-induced increase in both 2-[11C]thymidine FRT and plasma deoxyuridine levels was statistically significantly correlated with AG337 exposure (r = 1.00, P =.01 for both). CONCLUSIONS: AG337 administration was associated with increased tumor tracer retention that was consistent with tumor cell uptake of exogenous 2-[11C]thymidine as a result of TS inhibition. 2-[11C]Thymidine PET can be used to measure thymidine salvage kinetics directly in the tissue of interest.

Journal article

Gupta N, Price PM, Aboagye EO, 2002, PET for in vivo pharmacokinetic and pharmacodynamic measurements, EUROPEAN JOURNAL OF CANCER, Vol: 38, Pages: 2094-2107, ISSN: 0959-8049

Journal article

Aboagye EO, Salaam A, Gupta N, Brock C, Price Pet al., 2002, What new pharmacokinetic information can molecular imaging provide us, 14th EORTC/NCI/AACR Symposium on Molecular Targets and Cancer Therapeutics, Publisher: PERGAMON-ELSEVIER SCIENCE LTD, Pages: S12-S12, ISSN: 0959-8049

Conference paper

This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.

Request URL: http://wlsprd.imperial.ac.uk:80/respub/WEB-INF/jsp/search-html.jsp Request URI: /respub/WEB-INF/jsp/search-html.jsp Query String: id=00169625&limit=30&person=true&page=10&respub-action=search.html